Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PML::RARA status confers therapeutic sensitivity to Arsenic trioxide in patients with APL with PML-RARA.
This statement is based on a regulatory approval from the Health Service Executive:
Treatement of patients with relapsed or refractory APL after ATRA/chemotherapy